title: Pharmacological strategies for improving diastolic dysfunction in the setting of chronic pulmonary hypertension.
abstract: BACKGROUND
  Right ventricular (RV) hypertrophy is an adaptive process that occurs in the setting of chronic pulmonary hypertension (CPH) and can lead to alterations in normal RV diastolic properties. This study was designed to investigate the effects of NO and milrinone on RV diastolic dysfunction in the setting of CPH and RV hypertrophy by use of a canine model of monocrotaline pyrrole (MCTP)-induced CPH.
  
  
  RESULTS
  Sixteen mongrel dogs (22 to 24 kg) were used. Animals underwent percutaneous pulmonary artery (PA) catheterization to measure pulmonary hemodynamics before and 8 weeks after injection of 3 mg/kg MCTP (n=8) or placebo (control, n=8). Eight weeks after injection, all hearts were instrumented with a PA flow probe, sonomicrometric dimension transducers, and micromanometers. Data were collected at baseline and after both NO and milrinone administration. Diastolic properties were quantified by use of the end-diastolic pressure-volume relationship and the time constant of ventricular isovolumic relaxation. Eight weeks after injection, significant increases in the PA pressure and pulmonary vascular resistance were observed in MCTP dogs. Significant worsening of RV diastolic function occurred in association with significant increases in the ratio of RV dry weight to LV+septal dry weight. NO and milrinone administration both led to significant improvements in RV diastolic properties.
  
  
  CONCLUSIONS
  In the setting of MCTP-induced CPH, significant worsening of RV diastolic function was observed in association with significant increases in the ratio of RV dry weight to LV+septal dry weight, suggesting that these changes are partially due to RV hypertrophy. The significant improvement in RV diastolic properties after both NO and milrinone administration suggests that these agents may be effective forms of pharmacological therapy for improving RV diastolic dysfunction in the setting of CPH.
authors.affiliation: Department of Surgery, Duke University Medical Center, Durham, NC, USA. epchen@itsa.ucsf.edu
authors.forename: E P
authors.initials: EP
authors.lastname: Chen
authors.forename: D M
authors.initials: DM
authors.lastname: Craig
authors.forename: H B
authors.initials: HB
authors.lastname: Bittner
authors.forename: R D
authors.initials: RD
authors.lastname: Davis
authors.forename: P
authors.initials: P
authors.lastname: Van Trigt
mesh_terms: D000280:Administration, Inhalation; D000818:Animals; D002316:Cardiotonic Agents / Q000008:administration & dosage*; D002908:Chronic Disease; D003971:Diastole / Q000187:drug effects; D004285:Dogs; D006352:Heart Ventricles / Q000503:physiopathology*; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000503:physiopathology*; D020105:Milrinone; D009569:Nitric Oxide / Q000008:administration & dosage*; D011728:Pyridones / Q000008:administration & dosage*
chemical_list: D002316:Cardiotonic Agents; D011728:Pyridones; D009569:Nitric Oxide; D020105:Milrinone